Aurinia Pharmaceutical Company recently announced that the phase IIB clinical study of its voclosporin therapy for active lupus nephritis, or lupus-related kidney disease, has been successful.
The study was able to help several study participants achieve complete remission from their health condition. These results are good news for people who have kidney disease from lupus.
“The results of this trial are welcomed and exciting news for people with lupus and their doctors who are eager to have more tolerable and effective treatment options,” Sandra Raymond, president and CEO of the Lupus Foundation of America, said. “Lupus-related kidney disease is one of the most serious and potentially life-threatening complications of lupus, affecting up to 60 percent of people with this autoimmune disease.”
Health experts believe that voclosporin will be useful for lupus nephritis patients.
“This trial of voclosporin is the first trial of a potential treatment for active lupus nephritis to reach its primary endpoint, offering hope to individuals with lupus that an improved quality of life can soon be achieved,” Raymond said. “We are excited for the potential that the data from this study represents, and we are eager to learn more details of additional analysis as they become available.”
